Long-term efficacy and toxicity of the FEC100 regimen

Adjuvant chemotherapy has been shown to be beneficial in patients with breast cancer, and anthracycline-containing regimens are more effective than non-anthracycline-containing ones. The French Adjuvant Study Group (FASG) compared FEC100 and FEC50 (fluorouracil [5-FU]/epirubicin [Ellence]/cyclophosp...

Full description

Saved in:

Bibliographic Details
Published in:	Oncology (Williston Park, N.Y.) Vol. 18; no. 14 Suppl 14; p. 56
Main Author:	Bonneterre, Jacques M
Format:	Journal Article
Language:	English
Published:	United States 01-12-2004
Subjects:	Adult Aged Antineoplastic Combined Chemotherapy Protocols - administration & dosage Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - economics Antineoplastic Combined Chemotherapy Protocols - therapeutic use Breast Neoplasms - drug therapy Breast Neoplasms - economics Breast Neoplasms - pathology Breast Neoplasms - surgery Cost-Benefit Analysis Cyclophosphamide - administration & dosage Disease-Free Survival Dose-Response Relationship, Drug Drug Costs Epirubicin - administration & dosage Female Fluorouracil - administration & dosage Heart Diseases - chemically induced Humans Leukemia, Myelomonocytic, Acute - chemically induced Lymph Nodes - pathology Lymphatic Metastasis Middle Aged Precursor Cell Lymphoblastic Leukemia-Lymphoma - chemically induced Time Factors Treatment Outcome
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Adjuvant chemotherapy has been shown to be beneficial in patients with breast cancer, and anthracycline-containing regimens are more effective than non-anthracycline-containing ones. The French Adjuvant Study Group (FASG) compared FEC100 and FEC50 (fluorouracil [5-FU]/epirubicin [Ellence]/cyclophosphamide [Cytoxan, Neosar]) in patients with node-positive breast cancer, with an endpoint of overall survival. After a median follow-up of 10 years, the benefit/risk ratio of the FEC100 regimen in patients with positive axillary nodes is strongly positive. Furthermore, a medicoeconomic study showed that the cost per year of life saved was very low--approximately 1000 Euros.
ISSN:	0890-9091